BR0114483A - Derivado de pirazol para tratamento de doenças viróticas - Google Patents

Derivado de pirazol para tratamento de doenças viróticas

Info

Publication number
BR0114483A
BR0114483A BR0114483-9A BR0114483A BR0114483A BR 0114483 A BR0114483 A BR 0114483A BR 0114483 A BR0114483 A BR 0114483A BR 0114483 A BR0114483 A BR 0114483A
Authority
BR
Brazil
Prior art keywords
treatment
compounds
viral diseases
pyrazole derivative
formula
Prior art date
Application number
BR0114483-9A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0114483A publication Critical patent/BR0114483A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE PIRAZOL PARA O TRATAMENTO DE DOENçAS VIRóTICAS". A invenção refere-se aos novos e conhecidos derivados de pirazol, a um processo para sua produção, às composições farmacêuticas e ao uso de tais compostos na medicina. Em particular, os compostos da fórmula (I) são inibidores da enzima de transcriptase reversa do vírus da imunodeficiência humana que está envolvida na replicação virótica. Por conseguinte, os compostos desta invenção podem ser vantajosamente usados como agentes terapêuticos para processo mediado por HIV. Especificamente a invenção descreve o uso dos compostos da fórmula (I) para o tratamento de doenças mediadas pelo vírus da imunodeficiência humana (HIV) ou para a preparação de um medicamento para tal tratamento.
BR0114483-9A 2000-10-10 2001-10-04 Derivado de pirazol para tratamento de doenças viróticas BR0114483A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0024795.7A GB0024795D0 (en) 2000-10-10 2000-10-10 Pyrazole derivatives for the treatment of viral diseases
PCT/EP2001/011474 WO2002030907A1 (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases

Publications (1)

Publication Number Publication Date
BR0114483A true BR0114483A (pt) 2003-07-01

Family

ID=9900999

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114483-9A BR0114483A (pt) 2000-10-10 2001-10-04 Derivado de pirazol para tratamento de doenças viróticas

Country Status (29)

Country Link
US (2) US6699887B2 (pt)
EP (1) EP1326843A1 (pt)
JP (1) JP4015548B2 (pt)
KR (1) KR100534158B1 (pt)
CN (2) CN1680333A (pt)
AR (1) AR030858A1 (pt)
AU (2) AU2165102A (pt)
BR (1) BR0114483A (pt)
CA (1) CA2423515A1 (pt)
CZ (1) CZ20031297A3 (pt)
EC (1) ECSP034547A (pt)
GB (1) GB0024795D0 (pt)
GT (1) GT200100201A (pt)
HK (1) HK1061021A1 (pt)
HR (1) HRP20030251A2 (pt)
HU (1) HUP0302722A2 (pt)
IL (1) IL154875A0 (pt)
MA (1) MA26951A1 (pt)
MX (1) MXPA03003070A (pt)
NO (1) NO20031615L (pt)
NZ (1) NZ524740A (pt)
PA (1) PA8530301A1 (pt)
PE (1) PE20020750A1 (pt)
PL (1) PL362918A1 (pt)
RU (1) RU2270832C2 (pt)
UY (1) UY26956A1 (pt)
WO (1) WO2002030907A1 (pt)
YU (1) YU27203A (pt)
ZA (1) ZA200302519B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2423868C (en) * 2000-09-29 2011-06-07 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
GB0113524D0 (en) 2001-06-04 2001-07-25 Hoffmann La Roche Pyrazole derivatives
US7230025B2 (en) 2002-09-26 2007-06-12 Pfizer, Inc. Pyrazole derivatives
WO2004029042A1 (en) * 2002-09-26 2004-04-08 Pfizer Limited Pyrazole derivatives as reverse transcriptase inhibitors
AU2003263455A1 (en) 2002-09-26 2004-04-19 Pfizer Inc. Pyrazole amides for treating hiv infections
GB0223232D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
GB0223234D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
CA2518823A1 (en) 2003-03-24 2004-10-07 F.Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
DK2433943T3 (da) 2004-07-01 2013-12-16 Daiichi Sankyo Co Ltd Mellemprodukter til thienopyrazol-derivater med PDE7-inhibitorisk aktivitet
US20070005049A1 (en) * 2005-06-30 2007-01-04 Comben Richard H Apparatus and Method of Treating Urinary Incontinence by Heating Urethra
WO2008004096A1 (en) * 2006-07-05 2008-01-10 Pfizer Products Inc. Pyrazole derivatives as cytochrome p450 inhibitors
RU2451676C2 (ru) 2006-08-16 2012-05-27 Ф.Хоффманн-Ля Рош Аг Ненуклеозидные ингибиторы обратной транскриптазы
GB0713479D0 (en) * 2007-07-11 2007-08-22 Syngenta Participations Ag Substituted aromatic heterocyclic compounds as fungicides
RU2495878C2 (ru) 2007-12-21 2013-10-20 Ф.Хоффманн-Ля Рош Аг Гетероциклические антивирусные соединения
GB0823000D0 (en) * 2008-12-17 2009-01-28 Syngenta Participations Ag Isothiazole and pyrazole derivatives with plant growth regulating properties
CN102333781B (zh) 2009-02-25 2014-06-11 第一三共株式会社 三环吡唑并嘧啶衍生物
FR2951549B1 (fr) 2009-10-15 2013-08-23 Olivier Schussler Procede d'obtention de bioprotheses medicales implantables
WO2012026433A1 (ja) 2010-08-23 2012-03-01 第一三共株式会社 三環性ピラゾロピリミジン誘導体のフリー体結晶
WO2012026434A1 (ja) 2010-08-23 2012-03-01 第一三共株式会社 三環性ピラゾロピリミジン誘導体の結晶
WO2014074628A1 (en) * 2012-11-08 2014-05-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compounds for treating hiv and methods for using the compounds
US9925190B2 (en) 2015-02-16 2018-03-27 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting HIV-1 Nef
JP7301042B2 (ja) 2018-03-30 2023-06-30 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除組成物
US20220380341A1 (en) * 2018-10-18 2022-12-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibitors of hiv-1 nef for the treatment of hiv disease
FR3121927B1 (fr) 2021-04-19 2023-03-31 Eiffage Genie Civil Terrassement Procédé d’inertage des boues d’excavation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015060A1 (en) 1992-01-22 1993-08-05 Nissan Chemical Industries, Ltd. Substituted pyrazole derivative and agrohorticultural bactericide
US6005109A (en) 1997-10-30 1999-12-21 Pflizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
WO2006027423A1 (fr) * 2004-08-09 2006-03-16 Simag Developpement Dispositif de saisie comportant un capteur optique suivi d’un moyen de filtrage

Also Published As

Publication number Publication date
WO2002030907A1 (en) 2002-04-18
CA2423515A1 (en) 2002-04-18
US20040192752A1 (en) 2004-09-30
CN1191239C (zh) 2005-03-02
KR20030046492A (ko) 2003-06-12
CZ20031297A3 (cs) 2004-01-14
US6699887B2 (en) 2004-03-02
AR030858A1 (es) 2003-09-03
AU2165102A (en) 2002-04-22
EP1326843A1 (en) 2003-07-16
MXPA03003070A (es) 2003-07-14
RU2003112610A (ru) 2005-02-20
AU2002221651B2 (en) 2006-10-19
PL362918A1 (en) 2004-11-02
ECSP034547A (es) 2003-05-26
JP2004511469A (ja) 2004-04-15
RU2270832C2 (ru) 2006-02-27
CN1680333A (zh) 2005-10-12
NO20031615L (no) 2003-05-23
PA8530301A1 (es) 2002-07-30
JP4015548B2 (ja) 2007-11-28
GB0024795D0 (en) 2000-11-22
US7183296B2 (en) 2007-02-27
HK1061021A1 (en) 2004-09-03
US20030018197A1 (en) 2003-01-23
IL154875A0 (en) 2003-10-31
ZA200302519B (en) 2004-06-30
UY26956A1 (es) 2002-04-26
NZ524740A (en) 2005-09-30
NO20031615D0 (no) 2003-04-09
HUP0302722A2 (hu) 2003-12-29
YU27203A (sh) 2006-05-25
KR100534158B1 (ko) 2005-12-06
GT200100201A (es) 2002-05-23
CN1469865A (zh) 2004-01-21
MA26951A1 (fr) 2004-12-20
PE20020750A1 (es) 2002-08-21
HRP20030251A2 (en) 2005-02-28

Similar Documents

Publication Publication Date Title
BR0114483A (pt) Derivado de pirazol para tratamento de doenças viróticas
BR0208572A (pt) Derivados de aminopiperidina
BRPI0208811B8 (pt) derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos
BR9811055A (pt) Composto , uso do mesmo, composição farmacêutica, e, processo para tratamento de doença ou condição médica mediada pelo fator xa
BR0108600A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória
BR0210838A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com glicogênio sintase quinase-3, e de doenças, e medicação contraceptiva, e, processos para a preparação de um composto
BR0215240A (pt) Derivados de calcona e seu uso no tratamento de doenças
BR9808540A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica e processo para preparação dos mesmos, uso de um composto, e, processo para produzir a imunossupressão
BR0212008A (pt) Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste
LV12632A (lv) Pyrazoline derivatives their preparation and application as medicaments
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
TR199901006T2 (xx) Heterosiklik t�revler.
BR9909976A (pt) Composto, processo para a obtenção de compostos, derivado litiado, composições farmacêuticas, e, processos de tratamento de doenças relacionadas com hiv e de tratamento de infecção de hiv
BR9809481A (pt) Composto, processo para sua preparação, uso do mesmo, composição farmacêutica, e, processos para sua preparação, para efetuar a imunossupressão e para tratar ou reduzir o risco de uma doença obstrutiva reversìvel das vias aéreas em um paciente
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BR9714059A (pt) S-omeprazol em uma forma neutra, processo para preparar o mesmo, uso deste, composição farmacêutica, e, processo para tratar uma condição relacionada com ácido gástrico.
HUP9902121A2 (hu) Gonadotropin-leadó hormon antagonista hatású indolszármazékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
BR0206435A (pt) Composto, composição farmacêutica, métodos de tratar a angiogênese em um paciente, de tratar distúrbios relacionados com kdr e proliferativos em um mamìfero, uso de um composto, e, processo para preparar compostos
PT88930A (pt) Processo para a preparacao de novos analogos de nucleosidos e de composicoes farmaceuticas que os contem
BR9907270A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BR0210158A (pt) Derivados de pirazol como inibidores da transcriptase reversa do hiv
BR9910179A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para tratar uma doença ou condição mediada por fator xa em um animal de sangue quente
BR0112241A (pt) Derivados de pirrol para o tratamento de aids

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.